FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

The FDA lists a supplemental application for Fintepla (fenfluramine) from UCB, Inc., indicating potential changes to labeling or indications for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome

Drugs mentioned

• Fintepla (Fenfluramine)

Snippet

SUPPL AP for FINTEPLA (FENFLURAMINE)